A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination.
Emerg Microbes Infect
; 11(1): 250-259, 2022 Dec.
Article
in English
| MEDLINE | ID: covidwho-1585240
ABSTRACT
Testing and vaccination have been major components of the strategy for combating the ongoing COVID-19 pandemic. In this study, we have developed a quantitative anti-SARS-CoV-2 spike (S1) IgG antibody assay using a fingerstick dried blood sample. We evaluated the feasibility of using this high-throughput and quantitative anti-SARS-CoV-2 spike (S1) IgG antibody testing assay in vaccinated individuals. Fingerstick blood samples were collected and analyzed from 137 volunteers before and after receiving the Moderna or Pfizer mRNA vaccine. Anti-SARS-CoV-2 S1 IgG antibody could not be detected within the first 7 days after receiving the first vaccine dose, however, the assay reliably detected antibodies from day 14 onwards. In addition, no anti-SARS-CoV-2 nucleocapsid (N) protein IgG antibody was detected in any of the vaccinated or healthy participants, indicating that the anti-SARS-CoV-2 S1 IgG assay is specific for the mRNA vaccine-induced antibodies. The S1 IgG levels detected in fingerstick samples correlated with the levels found in venous blood plasma samples and with the efficacy of venous blood plasma samples in the plaque reduction neutralization test (PRNT). The assay displayed a limit of quantification (LOQ) of 0.59â
µg/mL and was found to be linear in the range of 0.51-1000â
µg/mL. Finally, its clinical performance displayed a Positive Percent Agreement (PPA) of 100% (95% CI 0.89-1.00) and a Negative Percent Agreement (NPA) of 100% (95% CI 0.93-1.00). In summary, the assay described here represents a sensitive, precise, accurate, and simple method for the quantitative detection and monitoring of post-vaccination anti-SARS-CoV-2 spike IgG responses.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Specimen Handling
/
Immunoassay
/
High-Throughput Screening Assays
/
COVID-19 Vaccines
/
COVID-19 Serological Testing
/
SARS-CoV-2
/
COVID-19
Type of study:
Diagnostic study
/
Experimental Studies
/
Prognostic study
Topics:
Vaccines
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
Emerg Microbes Infect
Year:
2022
Document Type:
Article
Affiliation country:
22221751.2021.2023328
Similar
MEDLINE
...
LILACS
LIS